Table 1.
Baseline information of prospective and validation cohort
| Prospective cohort | |||
|---|---|---|---|
| Characteristic | ATB group (n = 43) | LTBI group (n = 49) | P value |
| Age (average) | |||
| 44.0 | 49.7 | 0.057 | |
| Gender | |||
| Male (%) | 30 (69.8%) | 21 (42.9%) | 0.012 |
| Female (%) | 13 (30.2%) | 28 (57.1%) | |
| T-SPOT.TB | |||
| Panel A, spot count | 88 | 31 | 0.002 |
| Panel B, spot count | 141 | 41 | 0.009 |
| Contact with ATB | |||
| Yes (%) | 2 (4.7%) | 49 (100%) | / |
| No (%) | 41 (95.3%) | 0 (0%) | |
| BCG vaccination history | |||
| Yes (%) | 6 (14.0%) | 31 (63.3%) | 0.000 |
| No/cannot remember (%) | 37 (86.0%) | 18 (36.7%) | |
| Clinical manifestations | |||
| Coughing with expectoration (%) | 36 (83.7%) | 17 (34.7%) | 0.000 |
| Chest tightness or pain (%) | 4 (9.3%) | 0 (0%) | 0.044 |
| Hemoptysis (%) | 3 (7.0%) | 0 (0%) | 0.098 |
| Night sweats (%) | 1 (2.3%) | 1 (2.0%) | 1.000 |
| Fever (%) | 1 (2.3%) | 1 (2.0%) | 1.000 |
| Inappetence (%) | 0 (%) | 0 (0%) | / |
| Lung cavity (%) | 17 (39.5%) | / | / |
| Comorbidity | |||
| Diabetes mellitus (%) | 5 (11.6%) | 1 (2.0%) | 0.094 |
| CHB (%) | 6 (16.3%) | 2 (4.1%) | 0.140 |
| HIV (%) | 0 (0%) | 0 (0%) | / |
| Hypertension (%) | 1 (2.3%) | 5 (10.2%) | 0.209 |
| Silicosis (%) | 1 (2.3%) | 0 (0%) | 0.467 |
| Validation cohort | |||
|---|---|---|---|
| Characteristic | LTBI (n = 104) | ATB (n = 209) | P value |
| Gender | |||
| Male (%) | 43 | 134 | 0.0001 |
| Female (%) | 56 | 66 | |
| Age | 45.17 ± 1.527 | 47.80 ± 1.449 | 0.2621 |
| Nationality | |||
| Han | 104 | 209 | – |
| District | |||
| Chongqing | 61 | 54 | < 0.0001 |
| Around Shanghai | 43 | 155 |
The baseline information of patients in prospective and validation cohort
ATB active tuberculosis, LTBI latent tuberculosis infection, BCG Bacillus Calmette-Guérin, CHB chronic hepatitis B, HIV human immunodeficiency virus